Sun Pharma Licenses Deuruxolitinib for Alopecia from Aclaris
December 6, 2023 11:04
Sun Pharma has secured exclusive rights to deuruxolitinib for treating alopecia areata and androgenetic alopecia from Aclaris Therapeutics. The agreement includes an upfront payment of USD 15 million.